Personalized treatment of cholangiocellular carcinoma (CCA)

2Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cholangiocellular carcinoma (CCA) is one of the primary liver tumors and overall represents a rare malignancy; however, in recent years the incidence, particularly of intrahepatic CCA (iCCA) has increased worldwide. Due to the high mortality, CCAs cause a significant proportion of cancer-related deaths also in Germany. Because the diagnosis is often made in advanced stages of the disease, in many cases a surgical approach with curative intention is not possible. For locally advanced or metastatic CCA the combination of gemcitabine and cisplatin currently remains the only approved systemic treatment. As the average survival time is only approximately 12 months even under first-line treatment with gemcitabine/cisplatin, research is focused on developing new molecularly targeted and immunological treatment options. Various studies are currently being carried out to investigate approval options for targeted treatment, which could be considered for genetically altered tumors, e.g. in fibroblast growth factor receptor (FGFR) fusion and isocitrate dehydrogenase (IDH) mutations. Additionally, initial clinical data on immune checkpoint inhibitors are available for CCA. Due to the complex selection and partially limited applicability of current treatment options in patients with CCA, an early collaboration with a gastroenterology and oncology center with the possibility of supervision by a tumor board consisting of gastroenterological oncologists, surgeons, radiologists and radio-oncologists or in advanced stages by a molecular tumor board is essential.

References Powered by Scopus

PD-1 blockade in tumors with mismatch-repair deficiency

7731Citations
N/AReaders
Get full text

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

3536Citations
N/AReaders
Get full text

The Global Burden of Cancer 2013

2502Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation

3Citations
N/AReaders
Get full text

IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jödicke, L., Zender, L., & Malek, N. P. (2020, February 1). Personalized treatment of cholangiocellular carcinoma (CCA). Internist. Springer Medizin. https://doi.org/10.1007/s00108-019-00723-w

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

67%

Professor / Associate Prof. 1

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Biochemistry, Genetics and Molecular Bi... 1

50%

Save time finding and organizing research with Mendeley

Sign up for free